First name
James
Middle name
D
Last name
St Louis

Title

Fourth Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report.

Year of Publication

2020

Number of Pages

Date Published

2020 Oct 08

ISSN Number

1552-6259

Abstract

<p><strong>BACKGROUND: </strong>Pedimacs, an originally NIH-sponsored U.S. database, provides a platform to understand the population of children supported with VADs during this time of increasing numbers, new devices, expanding indications, and improved outcomes.</p>

<p><strong>METHODS: </strong>Between 9/19/12-12/31/19, 44 hospitals implanted 1031 devices in 856 patients under 19 years-of-age.</p>

<p><strong>RESULTS: </strong>Overall, diagnosis was cardiomyopathy in 497(58%), congenital heart disease(CHD) in 216(25%), myocarditis in 85(10%), and other in 58(7%). Positive outcome (alive on device or bridge to transplantation/recovery) occurred in 82% at 6-months. The patient cohort for implantable continuous flow(IC) pumps (n=365)[age:13.2+/-3.9yrs., 18% INTERMACS profile-1, 23% intubated at implant, 16% with CHD] was significantly different from the paracorporeal continuous flow(PC) pump cohort (n=212)[age:3.6+/-4.9yrs, 46% INTERMACS profile-1, 81% intubated, 42% CHD] and the paracorporeal pulsatile(PP) pump cohort (n=230)[age:2.7 +/-3.5yrs, 31% INTERMACS profile-1, 76% intubated, 26% CHD]. Consistent with their cohort composition, positive outcomes at 6 months based on device type were IC-92%, PC-68%, and PP-81%. The incidence of cerebrovascular accidents(CVA) in the IC, PC, and PP cohorts is 7%, 14% and 15%, respectively.</p>

<p><strong>CONCLUSIONS: </strong>IC VADs, the most common VAD-type placed in children, are associated with improved outcomes compared to PP/PC devices, though PP/PC devices are limited to supporting our most challenging patients. Noteworthy, the incidence of CVA for pediatric VADs has significantly decreased and is now 11% overall. This report demonstrates again that although often attributed to age, size, or device type, much of the burden in mortality and adverse events is correlated to the patient's overall state at VAD implantation.</p>

DOI

10.1016/j.athoracsur.2020.09.003

Alternate Title

Ann Thorac Surg

PMID

33039359
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Third Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report: Pre-Implant Characteristics and Outcomes.

Year of Publication

2019

Number of Pages

Date Published

2019 Feb 25

ISSN Number

1552-6259

Abstract

<p><strong>BACKGROUND: </strong>The influence of ventricular assist device (VAD) use in the care of children with end-stage heart failure is growing rapidly through increasing numbers, new devices, expanding indications, and improving outcomes. Pedimacs, a NIH-sponsored U.S. database, provides a platform to understand this emerging population.</p>

<p><strong>METHODS: </strong>Between 9/19/12-12/31/17, 30 hospitals implanted 508 devices in 423 patients under 19 years-of-age. This past year was one of evolution for the Database as its management was transitioned to the Society of Thoracic Surgery, therefore data from institutions not under contract by August 1 2018 was not included in this report.</p>

<p><strong>RESULTS: </strong>Of the 423 patients, the diagnosis was cardiomyopathy in 261 (62%), myocarditis in 48 (11%), other in 28 (7%) and congenital heart disease in 86 (20%) with 52 of these patients having single ventricle physiology. The two most common support strategies included LVAD-342 (81%) and BiVAD-64 (15%). Positive Outcome (alive on device or bridge to transplantation/recovery) was 80% at 6-months (overall mortality of 20%). The patient cohort for implantable continuous flow (IC) pumps (n=197) [age at implant 13.4+/-3.8yrs., 19% INTERMACS profile-1, 21% intubated at implant and 12% with CHD] was significantly different from the paracorporeal continuous flow (PC) pump cohort (n=79) [age 3.9+/-5.2yrs, 49% INTERMACS profile-1, 86% intubated at implant, and 38% with CHD] and the paracorporeal pulsatile (PP) pump cohort (n=121) [age 3.3+/-3.9yrs, 41% INTERMACS profile-1, 77 % intubated at implant, and 21% with CHD]. Consistent with their cohort composition, device type positive outcomes at 6 months were PC-63%, PP-77% and IC-92%. Using Parametric Hazard Modeling, an early hazard for death was associated with INTERMACS profile-1, BiVAD, percutaneous devices, PC devices, small volume institutions, low age and low weight, while a constant hazard was associated with intubation and liver dysfunction at time of implant.</p>

<p><strong>CONCLUSIONS: </strong>IC VADs are the most common VAD type placed in children. The positive outcomes for the IC VADs are &gt;90% at 6 months, which may represent our field's maturation in both patient selection and timing of implantation. Currently the PP/PC devices are limited to supporting our most challenging patients, those less than 20kg, and those with CHD. The introduction of new devices and our communities' commitment to shared learning and improvement will lead to more pediatric lives saved by VAD support, and will also focus on improving the quality of life of children supported with VADs.</p>

DOI

10.1016/j.athoracsur.2019.01.038

Alternate Title

Ann. Thorac. Surg.

PMID

30817920
Inner Banner
Publication Image
Inner Banner
Publication Image

Title

Second annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) report: Pre-implant characteristics and outcomes.

Year of Publication

2018

Number of Pages

38-45

Date Published

2018 Jan

ISSN Number

1557-3117

Abstract

<p><strong>BACKGROUND: </strong>Expanded use of pediatric ventricular assist devices (VADs) has decreased mortality in children awaiting heart transplantation. Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs), a National Heart, Lung, and Blood Institute-sponsored North American database, provides a platform to understand this emerging population.</p>

<p><strong>METHODS: </strong>Between September 2012 and September 2016, patients aged younger than 19 years who underwent VAD implantation were enrolled in Pedimacs. FDA approved durable devices as well as temporary support devices were included. The second annual report updates the current Pedimacs data. Patients implanted with temporary devices are included in Pedimacs and this analysis includes this group of paracorporeal continuous flow VADs.</p>

<p><strong>RESULTS: </strong>Over the 4 years, 42 hospitals implanted 432 devices in 364 patients less than 19 yrs of age. Diagnoses included cardiomyopathy in 223 (61%), myocarditis in 41 (11%), and congenital heart disease in 77 (21%), of which 48 had single-ventricle physiology. At implant, 87% were at Intermacs patient profile 1 or 2. The age distribution of children (59% male) supported on VAD included 69 (19%) aged younger than 1 year, 66 (18%) aged 1 to 6 years, 56 (15%) aged 6 to 10 years, and 173 (48%) aged 11 to 19 years. Median follow-up was 2.2 months (range, 1 day to 41.5 months). Median (interquartile) age at implant was 1.7 (0.3-10.0) years for paracorporeal continuous-flow pumps (n = 60), 1.7 (0.4-5.3) years for paracorporeal pulsatile pumps (n = 105), and 15.0 (11.3-16.9) years for implantable continuous-flow pumps (n = 174). Support strategies included LVAD in 293 (80%), biventricular device in 55 (15%), and total artificial heart in 8 (2%). Nearly 50% of patients underwent transplantation within 6 months, with overall mortality of 19%. Adverse event burden continues to be high.</p>

<p><strong>CONCLUSIONS: </strong>Pedimacs constitutes the largest longitudinal pediatric VAD registry. Preimplant data across centers will be helpful at creating shared protocols with which to improve outcomes. Adverse events continue to be the major challenge, especially among the young critically ill children with complex congenital disease.</p>

DOI

10.1016/j.healun.2017.06.017

Alternate Title

PMID

28965736
Inner Banner
Publication Image
Inner Banner
Publication Image